Dyne Therapeutics to Present at Upcoming Investor Conferences

DYN 11.07.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-13
Name of Upcoming Event:Guggenheim Inaugural Healthcare Innovation Conference
Date of Upcoming Event:2024-11-19
Name of Upcoming Event:Stifel 2024 Healthcare Conference
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference
Full Press ReleaseSEC FilingsOur DYN Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.10.2025 - ACHIEVE Clinical Update

Recent Filings

  • 01.10.2025 - 8-K Current report
  • 01.10.2025 - EX-99.1 EX-99.1
  • 12.11.2024 - 144 Report of proposed sale of securities
PDF Version

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) --Dyne Therapeutics, Inc.(Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following upcoming investor conferences:

  • Guggenheim Inaugural Healthcare Innovation Conference,fireside chat on Wednesday, November 13, 2024 at 4:00 p.m. ET in Boston
  • Stifel 2024 Healthcare Conference,fireside chat on Tuesday, November 19, 2024 at 3:00 p.m. ET in New York
  • Piper Sandler 36thAnnual Healthcare Conference, fireside chat on Tuesday, December 3, 2024 at 3:00 p.m. ET in New York

A live webcast of each presentation will be available in the Investors & Media section of Dyne’s website athttps://investors.dyne-tx.com/news-and-events/events-and-presentationsand a replay will be accessible for 90 days.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCETM platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visithttps://www.dyne-tx.com/, and follow us onX,LinkedInandFacebook.

Contact:Amy Reillyareilly@dyne-tx.com857-341-1203

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com